NASDAQ:GDRX

GoodRx Competitors

$40.15

+0.69 (+1.75 %)

(As of 04/9/2021 12:00 AM ET)

Add

Compare

Today's Range

$39.10

Now: $40.15▼

$40.20

50-Day Range

$35.03

MA: $41.48▼

$54.03

52-Week Range

$33.39

Now: $40.15▼

$64.22

Volume1.14 million shs

Average Volume2.25 million shs

Market Capitalization$15.74 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

GoodRx (NASDAQ:GDRX) Vs. WDAY, BILI, VRSK, RNG, STNE, and ZEN

Should you be buying GDRX stock or one of its competitors? Companies in the industry of "data processing & preparation" are considered alternatives and competitors to GoodRx, including Workday (WDAY), Bilibili (BILI), Verisk Analytics (VRSK), RingCentral (RNG), StoneCo (STNE), and Zendesk (ZEN).

GoodRx vs. Workday Stock

Workday (NASDAQ:WDAY) and GoodRx (NASDAQ:GDRX) are both large-cap computer and technology companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Earnings and Valuation

This table compares Workday and GoodRx's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Workday	$3.63 billion	17.26	$-480,670,000.00	($1.42)	-181.42
GoodRx	$388.22 million	40.55	$66.05 million	N/A	N/A

GoodRx has lower revenue, but higher earnings than Workday.

Insider and Institutional Ownership

68.0% of Workday shares are held by institutional investors. Comparatively, 43.4% of GoodRx shares are held by institutional investors. 26.5% of Workday shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Workday and GoodRx's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Workday	-10.77%	-10.56%	-3.90%
GoodRx	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations for Workday and GoodRx, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Workday	1	9	19	0	2.62
GoodRx	1	6	7	0	2.43

Workday presently has a consensus price target of $263.2222, indicating a potential upside of 2.18%. GoodRx has a consensus price target of $52.3571, indicating a potential upside of 30.40%. Given GoodRx's higher probable upside, analysts plainly believe GoodRx is more favorable than Workday.

Summary

GoodRx beats Workday on 6 of the 11 factors compared between the two stocks.

GoodRx vs. Bilibili Stock

Bilibili (NASDAQ:BILI) and GoodRx (NASDAQ:GDRX) are both large-cap computer and technology companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Earnings and Valuation

This table compares Bilibili and GoodRx's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bilibili	$973.59 million	38.24	$-185,150,000.00	($0.57)	-185.61
GoodRx	$388.22 million	40.55	$66.05 million	N/A	N/A

GoodRx has lower revenue, but higher earnings than Bilibili.

Profitability

This table compares Bilibili and GoodRx's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bilibili	-25.28%	-30.90%	-12.85%
GoodRx	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations for Bilibili and GoodRx, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bilibili	0	2	9	0	2.82
GoodRx	1	6	7	0	2.43

Bilibili presently has a consensus price target of $66.0455, indicating a potential downside of 37.58%. GoodRx has a consensus price target of $52.3571, indicating a potential upside of 30.40%. Given GoodRx's higher probable upside, analysts plainly believe GoodRx is more favorable than Bilibili.

Insider and Institutional Ownership

39.1% of Bilibili shares are held by institutional investors. Comparatively, 43.4% of GoodRx shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

GoodRx beats Bilibili on 7 of the 10 factors compared between the two stocks.

GoodRx vs. Verisk Analytics Stock

Verisk Analytics (NASDAQ:VRSK) and GoodRx (NASDAQ:GDRX) are both large-cap business services companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Earnings & Valuation

This table compares Verisk Analytics and GoodRx's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verisk Analytics	$2.61 billion	11.38	$449.90 million	$4.38	41.71
GoodRx	$388.22 million	40.55	$66.05 million	N/A	N/A

Verisk Analytics has higher revenue and earnings than GoodRx.

Profitability

This table compares Verisk Analytics and GoodRx's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Verisk Analytics	19.12%	36.42%	11.46%
GoodRx	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings for Verisk Analytics and GoodRx, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verisk Analytics	0	4	8	0	2.67
GoodRx	1	6	7	0	2.43

Verisk Analytics presently has a consensus price target of $195.4545, indicating a potential upside of 6.98%. GoodRx has a consensus price target of $52.3571, indicating a potential upside of 30.40%. Given GoodRx's higher probable upside, analysts clearly believe GoodRx is more favorable than Verisk Analytics.

Insider & Institutional Ownership

88.2% of Verisk Analytics shares are owned by institutional investors. Comparatively, 43.4% of GoodRx shares are owned by institutional investors. 2.6% of Verisk Analytics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Verisk Analytics beats GoodRx on 9 of the 11 factors compared between the two stocks.

GoodRx vs. RingCentral Stock

RingCentral (NYSE:RNG) and GoodRx (NASDAQ:GDRX) are both large-cap computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Earnings & Valuation

This table compares RingCentral and GoodRx's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RingCentral	$902.86 million	31.80	$-53,610,000.00	($0.19)	-1,670.00
GoodRx	$388.22 million	40.55	$66.05 million	N/A	N/A

GoodRx has lower revenue, but higher earnings than RingCentral.

Profitability

This table compares RingCentral and GoodRx's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RingCentral	-9.66%	-12.62%	-3.55%
GoodRx	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings for RingCentral and GoodRx, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RingCentral	0	0	21	1	3.05
GoodRx	1	6	7	0	2.43

RingCentral presently has a consensus price target of $431.7727, indicating a potential upside of 36.08%. GoodRx has a consensus price target of $52.3571, indicating a potential upside of 30.40%. Given RingCentral's stronger consensus rating and higher probable upside, research analysts clearly believe RingCentral is more favorable than GoodRx.

Insider & Institutional Ownership

86.3% of RingCentral shares are owned by institutional investors. Comparatively, 43.4% of GoodRx shares are owned by institutional investors. 11.0% of RingCentral shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

RingCentral beats GoodRx on 7 of the 12 factors compared between the two stocks.

GoodRx vs. StoneCo Stock

StoneCo (NASDAQ:STNE) and GoodRx (NASDAQ:GDRX) are both large-cap computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Earnings & Valuation

This table compares StoneCo and GoodRx's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
StoneCo	$626.01 million	30.04	$203.54 million	$0.70	96.87
GoodRx	$388.22 million	40.55	$66.05 million	N/A	N/A

StoneCo has higher revenue and earnings than GoodRx.

Profitability

This table compares StoneCo and GoodRx's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
StoneCo	26.05%	9.87%	3.69%
GoodRx	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings for StoneCo and GoodRx, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
StoneCo	0	4	7	0	2.64
GoodRx	1	6	7	0	2.43

StoneCo presently has a consensus price target of $66.20, indicating a potential downside of 2.37%. GoodRx has a consensus price target of $52.3571, indicating a potential upside of 30.40%. Given GoodRx's higher probable upside, analysts clearly believe GoodRx is more favorable than StoneCo.

Insider & Institutional Ownership

61.5% of StoneCo shares are owned by institutional investors. Comparatively, 43.4% of GoodRx shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

StoneCo beats GoodRx on 7 of the 9 factors compared between the two stocks.

GoodRx vs. Zendesk Stock

Zendesk (NYSE:ZEN) and GoodRx (NASDAQ:GDRX) are both large-cap computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Earnings & Valuation

This table compares Zendesk and GoodRx's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zendesk	$816.42 million	20.92	$-169,650,000.00	($1.19)	-121.29
GoodRx	$388.22 million	40.55	$66.05 million	N/A	N/A

GoodRx has lower revenue, but higher earnings than Zendesk.

Profitability

This table compares Zendesk and GoodRx's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zendesk	-19.24%	-22.55%	-6.13%
GoodRx	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings for Zendesk and GoodRx, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zendesk	0	3	12	0	2.80
GoodRx	1	6	7	0	2.43

Zendesk presently has a consensus price target of $143.00, indicating a potential downside of 0.93%. GoodRx has a consensus price target of $52.3571, indicating a potential upside of 30.40%. Given GoodRx's higher probable upside, analysts clearly believe GoodRx is more favorable than Zendesk.

Insider & Institutional Ownership

97.4% of Zendesk shares are owned by institutional investors. Comparatively, 43.4% of GoodRx shares are owned by institutional investors. 4.3% of Zendesk shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

GoodRx beats Zendesk on 6 of the 11 factors compared between the two stocks.